Newly released prostate cancer screening guidelines, the first new guidelines in a decade contain some significant changes.
It outlines who, when, how and how often men should be screened and assessed for this common cancer.
In this webcast on 1 September, GP, Associate Professor Ralph Audehm and urologist, Professor Jeremy Grummet explain how these changes will affect GP’s day to day clinical practice. In particular, they will focus on PSA testing, when it is appropriate, how the results should be interpreted depending on the patient, and the new recommendations in terms of further management when the PSA is found to be high.
How do the CPD options work?
- Attend the webcast and earn 2 hrs CPD in the Educational Activities category by attending the webcast lecture and completing the evaluation (RACGP & ACRRM approved)
- Complete the optional post-webcast quiz and earn 0.5 hrs CPD in the Reviewing Performance category (RACGP & ACRRM approved)
- Complete the optional Patient Case Review and earn a further 0.5 hrs CPD in the Reviewing Performance category (RACGP & ACRRM approved)
- Undertake the optional Micro Audit and gain 1 hrs CPD in the Measuring Outcomes category (RACGP & ACRRM approved)
Other professions can self-claim up to 4 hrs CPD.
Attendees will receive Certificate of Attendance about four weeks post-webcast.
Don’t miss out, REGISTER NOW.
Topics include:
New Prostate Cancer Screening Guidelines – Case-Based Explanation for GP
A/Prof Ralph Audehm
General Practitioner; Carlton Family Medical, Melbourne; Clinical Associate Professor, University of Melbourne, Department of General Practice
&
Prof Jeremy Grummet
Urological Surgeon; Director of Urology, Alfred Health, Melbourne
Newly released prostate cancer screening guidelines, the first new guidelines in a decade contain some significant changes in terms of who, when, how and how often men should be screened and assessed for this common cancer. How these changes will affect GP’s day to day clinical practice is the subject of this very pragmatic and practical discussion between GP, Associate Professor Ralph Audehm and urologist, Professor Jeremy Grummet. In particular, they will focus on PSA testing, when it is appropriate, how the results should be interpreted depending on the patient, and the new recommendations in terms of further management when the PSA is found to be high.
Acute Migraine Management
Dr Katherine Spira
Consultant Neurologist; Spira Neurology
Managing acute migraines is still fundamentally important for clinicians treating migraine patients, even in patients taking preventive therapy. In this talk, neurologist Dr Katherine Spira shares her recipe for effective treatment of the acute migraine and how this recipe can be finessed to ensure maximum effectiveness, minimum side effects and a resumption of normal functioning within 90 minutes of the migraine onset – the ultimate goal.
Continuous Glucose Monitoring Update – Why it will Soon Become Standard Care
A/Prof Gary Kilov AM
General Practitioner; Director, Launceston Diabetes Clinic; Clinical Associate Professor, University of Melbourne; Honorary Associate Professor, University of Sydney
Continuous Glucose Monitoring is now being recommended as the standard for management of any patient on intensive insulin therapy, not just those with type 1 diabetes. In this talk, Associate Professor Gary Kilov AM will present the evidence that supports current guidelines for CGM to be used in patients with type 2 diabetes who are on insulin. He will also address the logistics of commencing CGM in this cohort – including the when, how, for how long and choice of device. An important update in a rapidly evolving area of medicine.
Faecal Calprotectin – A Practical Guide to the Test and the New Item Number
Dr Aviv Pudipeddi
Staff Specialist Gastroenterologist; Clinical Senior Lecturer, University of Sydney
&
Dr David Lim
General Practitioner and Medical Educator, FRACGP
Faecal calprotectin testing is now readily accessible in primary care, making earlier diagnosis of inflammatory bowel disease more possible and more likely. In this session, GP, Dr David Lim interviews gastroenterologist, Dr Aviv Pudipeddi on the role of faecal calprotectin in clinical practice, including which patients are eligible for testing, when testing is appropriate and how the test results should be interpreted. Dr Pudipeddi will also discuss the role of faecal calprotectin in monitoring patients with confirmed inflammatory bowel disease, and how its use can be beneficial in preventing significant flares and avoiding complications of this chronic disease.
Tuesday 1 September 2026
Time:
7pm – 9pm AEST
6:30pm – 8:30pm ACDT
5pm – 7pm AWST
